We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Agilent (A) Q3 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Agilent Technologies (A - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.37 per share, reflecting an increase of 3.8% compared to the same period last year. Revenues are forecasted to be $1.66 billion, representing a year-over-year increase of 5.1%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Agilent metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Net Revenue- Life Sciences and Diagnostics Markets Segment' of $631.29 million. The estimate suggests a change of -19.3% year over year.
Analysts expect 'Net Revenue- Agilent Crosslab Group' to come in at $720.15 million. The estimate suggests a change of +75.2% year over year.
Analysts' assessment points toward 'Revenue by End Markets- Chemical and advanced materials' reaching $376.71 million. The estimate indicates a change of +5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue by End Markets- Environmental and Forensics' should arrive at $170.70 million. The estimate indicates a year-over-year change of +1.6%.
It is projected by analysts that the 'Revenue by End Markets- Diagnostics and Clinical' will reach $249.80 million. The estimate points to a change of +3.2% from the year-ago quarter.
The consensus estimate for 'Revenue by End Markets- Academia and Government' stands at $137.61 million. The estimate indicates a year-over-year change of +7.5%.
The average prediction of analysts places 'Revenue by End Markets- Pharmaceutical' at $581.31 million. The estimate indicates a year-over-year change of +7.7%.
According to the collective judgment of analysts, 'Revenue by End Markets- Food' should come in at $150.33 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Over the past month, Agilent shares have recorded returns of -2.7% versus the Zacks S&P 500 composite's +1.1% change. Based on its Zacks Rank #3 (Hold), A will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Agilent (A) Q3 Outlook: Wall Street Estimates for Key Metrics
In its upcoming report, Agilent Technologies (A - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.37 per share, reflecting an increase of 3.8% compared to the same period last year. Revenues are forecasted to be $1.66 billion, representing a year-over-year increase of 5.1%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Agilent metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Net Revenue- Life Sciences and Diagnostics Markets Segment' of $631.29 million. The estimate suggests a change of -19.3% year over year.
Analysts expect 'Net Revenue- Agilent Crosslab Group' to come in at $720.15 million. The estimate suggests a change of +75.2% year over year.
Analysts' assessment points toward 'Revenue by End Markets- Chemical and advanced materials' reaching $376.71 million. The estimate indicates a change of +5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue by End Markets- Environmental and Forensics' should arrive at $170.70 million. The estimate indicates a year-over-year change of +1.6%.
It is projected by analysts that the 'Revenue by End Markets- Diagnostics and Clinical' will reach $249.80 million. The estimate points to a change of +3.2% from the year-ago quarter.
The consensus estimate for 'Revenue by End Markets- Academia and Government' stands at $137.61 million. The estimate indicates a year-over-year change of +7.5%.
The average prediction of analysts places 'Revenue by End Markets- Pharmaceutical' at $581.31 million. The estimate indicates a year-over-year change of +7.7%.
According to the collective judgment of analysts, 'Revenue by End Markets- Food' should come in at $150.33 million. The estimate indicates a change of +4.4% from the prior-year quarter.
View all Key Company Metrics for Agilent here>>>Over the past month, Agilent shares have recorded returns of -2.7% versus the Zacks S&P 500 composite's +1.1% change. Based on its Zacks Rank #3 (Hold), A will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .